HY0001a / Huiyu Pharma - LARVOL DELTA

HY0001a: A novel antibody-drug conjugate (ADC) targeting CUB domain containing protein 1 (CDCP1) (AACR 2025) - "We identified CDCP1 as an excellent ADC TAA with great potential against multiple cancers. We discovered an antibody (HY0001) of high affinity, cancer cell-specific and efficiently internalization, and completed development of a preclinical candidate MMAE based ADC (HY0001a), which showed a great rationale for further clinical investigation to provide a novel cancer therapy."

ADC • Bladder Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Solid Tumor • CDCP1

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=261 | Recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | Withdrawn ➔ Recruiting | Trial completion date: May 2027 ➔ Sep 2027 | Trial primary completion date: Feb 2027 ➔ Jun 2027

Enrollment open • First-in-human • Trial completion date • Trial primary completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CDCP1

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | N=261 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Solid Tumor

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=261 | Not yet recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

New P1/2 trial • Solid Tumor